Retroviral delivery system
    2.
    发明授权
    Retroviral delivery system 失效
    逆转录病毒递送系统

    公开(公告)号:US06818209B1

    公开(公告)日:2004-11-16

    申请号:US09701014

    申请日:2000-11-22

    IPC分类号: A61K4800

    摘要: A retroviral delivery system capable of transducing a target site is described. The retroviral delivery system comprises a first nucleotide sequence coding for at least a part of an envelope protein; and one or more other nucleotide sequences derivable from a retrovirus that ensure transduction of the target site by the retroviral delivery system; wherein the first nucleotide sequence is heterologous with respect to at least one of the other nucleotide sequences; and wherein the first nucleotide sequence codes for at least a part of a rabies G protein or a mutant, variant, derivative or fragment thereof that is capable or recognising the target site.

    摘要翻译: 描述了能够转导靶位点的逆转录病毒递送系统。 逆转录病毒递送系统包含编码包膜蛋白的至少一部分的第一核苷酸序列; 以及一种或多种其它可逆转录病毒的核苷酸序列,其通过逆转录病毒递送系统确保靶位点的转导; 其中所述第一核苷酸序列相对于所述其它核苷酸序列中的至少一个是异源的; 并且其中所述第一核苷酸序列编码能够或识别所述靶位点的狂犬病G蛋白或突变体,变体,衍生物或片段的至少一部分。

    Method
    6.
    发明申请
    Method 审中-公开
    方法

    公开(公告)号:US20110269826A1

    公开(公告)日:2011-11-03

    申请号:US13128813

    申请日:2009-11-11

    IPC分类号: A61K48/00 A61P25/14 A61P25/16

    摘要: The present invention provides methods for: (i) treating and/or preventing Parkinson's disease in a subject without causing cognitive impairment by using dopamine replacement gene therapy to maintain or restore constant physiological dopaminergic tone in both the dorsal and ventral striatum of the subject; (ii) normalising neuronal electrical activity in basal ganglia and/or subthalamic nucleus in a Parkinson's disease subject; and (iii) treating and/or preventing dyskinesias associated with oral L-dopa administration in a Parkinson's disease subject by administration of a vector system for dopamine replacement gene therapy to the subject.

    摘要翻译: 本发明提供了以下方法:(i)通过使用多巴胺替代基因治疗在受试者的背侧和腹侧纹状体中维持或恢复不断的生理多巴胺能调节,治疗和/或预防受试者中的帕金森病,而不引起认知障碍; (ii)在帕金森病受试者的基底神经节和/或丘脑底核中归一化神经元电活动; 和(iii)通过向受试者施用用于多巴胺替代基因治疗的载体系统来治疗和/或预防与帕金森病患者口服左旋多巴给药相关的运动障碍。